Anaphylaxis is the most severe form of radiocontrast media (RCM) induced hypersensitivity and can be life-threatening if profound hypotension is combined. With increased use of iodine based RCM, related hypersensitivity is rapidly growing. However, the clinical characteristics and risk factors of RCM induced anaphylaxis accompanied by hypotension (anaphylactic shock) are not clearly defined. This study was performed to investigate the risk factors of RCM induced anaphylactic shock and the clinical value of RCM skin testing to identify causative agents in affected patients.

Methods: We analyzed the data of RCM induced anaphylaxis monitored by an inhospital pharmacovigilance center at a tertiary teaching hospital from January 2005 to December 2012 and compared the clinical features and skin test results according to the accompanying hypotension.

Results: Among total of 104 cases of RCM induced anaphylaxis, 34.6% of patients, developed anaphylaxis on their first exposure to RCM. Anaphylactic patients presenting with shock were older (57.4 vs. 50.1 years, \( p = 0.026 \)) and had a history of more frequently exposure to RCM (5.1±7.8 vs. 1.9±3.3, \( p = 0.004 \)) compared to those without hypotension. Among RCMs, hypotension was more frequent in anaphylaxis related to iopromide compared to other agents (85.0% vs. 61.4%, \( p = 0.011 \)). Skin tests were performed in 51 patients after development of RCM induced anaphylaxis. Overall skin test positivity to RCM was 64.7% and 81.8% in patients with anaphylactic shock.

Conclusion: RCM induced anaphylactic shock is related to multiple exposures to RCM and most patients showed skin test positivity to RCM.
anaphylaxis. Until recently, diagnostic value of RCM skin test has been underestimated and there are only a limited number of studies which evaluated the sensitivity of RCM skin testing to various RCM [10-12].

This study was performed to investigate the risk factors for the development of hypotension and the clinical value of RCM skin testing to identify causative agents in RCM induced anaphylaxis.

Methods

1. Study Subjects

This study protocol was approved by the institutional review board (IRB) of Seoul National University Hospital. Informed consents of patients were exempted from IRB because this study only used retrospective chart review data and all personal data was eliminated and coded as arbitrary number which were not personally-identifiable. Research data was accessed only by researchers using password.

We extracted all the cases of RCM induced hypersensitivity based on ATC code of causative agents (V08A: X-ray contrast media, iodinated, V08B: X-ray contrast media, non-iodinated)' and WHOART (ARRN: 0712 allergic reaction, 0713 anaphylactic shock, 0714 anaphylactoid reaction, 2237 anaphylactic reaction, 2268 documented hypersensitivity to administered drug) from our inhospital pharmacovigilance database collected from January 2005 to December 2012 at Seoul National University Hospital, in Seoul, Korea. Demographic and clinical data of affected patients such as age, sex, number of contrast exposures, laboratory test results, and underlying diseases based on ICD-10 were collected from electronic medical records. This study dealt only with CT procedures, not with other procedures such as cardiac catheterization or coronary angiography.

All the medical records were thoroughly re-evaluated by two allergy specialists to assess clinical features of anaphylaxis and the presence of previous contrast hypersensitivity reactions. Anaphylaxis was diagnosed if cases satisfied the criteria of anaphylaxis suggested by the National Institute of Allergy and Infectious Disease and Food Allergy and the Anaphylaxis Network [13]. Hypotension was considered as a systolic blood pressure less than 90 mmHg or greater than 30% decrease from an individual's baseline. [13] Hypotension unrelated with underlying diseases or other drugs was considered a manifestation of anaphylaxis.

After completing review, patients with anaphylaxis were classified into two groups depending on combined hypotension. We analyzed the data to identify risk factors for the development of anaphylactic shock by comparing anaphylactic patients combined with and without hypotension.

2. Skin Tests with Iodinated Contrast Agents

Skin tests were carried out after experiencing RCM induced anaphylaxis for those patients who agreed to undergo skin testing. Skin prick and intradermal tests were performed on the volar part of the forearm with 6 different RCM used in our hospital - iopromide (Ultravist®, Bayer Healthcare, Brussels, Belgium), iopamidol (Pamiray®, Dongkook Pharm. Co., Ltd, Korea), iomeprol (Iomeron®, Bracco, Milan, Italy), iohexol (Omnipaque®, Arnersham Health, Princeton, NJ), iodixanol (Visipaque®, Arnersham Health, Princeton, NJ), and iobitridol (Xenetics®, Guerbet, Gorinchem, Netherlands). Undiluted solution and 1:10 diluted solution were used for the skin prick test and intradermal
Histamine and normal saline were used as positive and negative control, respectively. The results were interpreted 15 minutes after the prick or the intradermal injection. Skin prick test was determined to be positive when wheal diameter was greater than 3 mm, and intradermal test was determined to be positive when wheal diameter increased 3 mm or more than the initial bleb [12].

The rate and factors contributing to the positivity of RCM skin test were analyzed.

3. Statistical Analysis

SPSS (version 19.0) was used to analyze the data. To compare the clinical features of two groups, Student t-test or Mann-Whitney test was used for continuous variables, and Chi-square test or Fisher’s exact test was used for categorical variables. To identify the risk factors related with anaphylactic shock and a positive skin test, multiple logistic regression was used. We included adjustment factors that had a P-value less than 0.1 in the univariate analysis, and other clinically important factors such as age and sex. A P-value less than 0.05 was considered statistically significant.

Results

1. Clinical Characteristics of the Study Subjects and Accompanied Anaphylaxis

A total number of contrast-enhanced CT scans during the study period was 632,513. A total of 104 cases of RCM related anaphylaxis were monitored during the study period. The incidence of contrast-induced anaphylaxis was 0.016%. As the total number of RCM use increased over the study period, the RCM related anaphylaxis also showed increasing tendency in number (Figure 1). The mean age was 55.6 ± 13.1 years and 41.3% (43/104) of them were male (Table 1).

| Number | Total (N, %) | Anaphylactic shock (N, %) | Normotensive anaphylaxis (N, %) | P-value |
|--------|-------------|--------------------------|-------------------------------|---------|
| Age (years)* | 104 | 78 | 26 | |
| Male gender, % | 43 (41.3) | 35 (44.9) | 8 (30.8) | 0.254 |
| Number of previous exposure to RCM* | 4.3 ± 7.1 | 5.1 ± 7.8 | 1.9 ± 3.3 | 0.004 |
| None | 36 (34.6) | 24 (30.8) | 12 (46.2) | 0.369 |
| 1 | 17 (16.3) | 13 (16.7) | 4 (15.4) | 0.069 |
| ≥2 | 51 (49.0) | 41 (52.6) | 10 (38.5) | 0.010 |
| Previous RCM reactions | 21/68 (30.9) | 18/54 (33.3) | 3/14 (21.4) | 0.362 |
| WBC count (/μL) | 5,844.7 ± 1,883.8 | 5,886 ± 1,921 | 5,617 ± 1,720 | 0.668 |
| Eosinophil count (/μL) | 62.0 ± 84.4 | 64.2 ± 86.9 | 50.0 ± 71.4 | 0.574 |

Continuous variables are expressed as mean ± standard deviation. *P < 0.05, †P < 0.01. Among the total 104 subjects, radiocontrast media involved in anaphylaxis could not be identified in seven patients who had experienced anaphylaxis prior to the introduction of electronic medical recording system.
first anaphylaxis. While anaphylaxis developed at the first exposure to RCM in 34.6% (36/104) of patients, 65.4% (68/104) of patients experienced anaphylaxis on repeated exposure to RCM and 21 of 68 (30.9%) had a milder form of hypersensitivity reactions in previous exposure to RCM.

Among hypersensitivity symptoms present in patients with anaphylaxis, cardiovascular symptoms were the most common (88/104, 84.6%), followed by skin symptoms (69/104, 66.3%) and respiratory symptoms (50/104, 48.1%) (Table 1). Most symptoms occurred within several minutes after the RCM injection. Seventy-eight patients experienced anaphylaxis with hypotension (anaphylactic shock) and 26 patients had anaphylaxis without hypotension.

2. Comparison of Clinical Characteristics According to the Development of Hypotension

Compared to anaphylactic patients without hypotension, patients who presented with anaphylactic shock were older (57.4 vs. 50.1 years, \( p = 0.026 \)) and had significantly higher number of previous RCM exposures (5.1 ± 7.8 vs. 1.9 ± 3.3, \( p = 0.004 \)). Of note, the number of patients who underwent previous CT more than two times was 52.6% and 38.5%, respectively in anaphylactic patients with and without hypotension. Especially, the proportion of previous exposure to RCM more than 5 times showed significant difference between anaphylactic patients with and without hypotension (35.4% vs. 9.1%, \( p = 0.018 \), Figure 2).

In terms of the causative contrast agent, hypotension was more frequent among anaphylaxis related to iopromide compared to other agents (85.0% vs. 61.4%, \( p = 0.011 \)). Iopromide use was more frequently observed in patients with hypotension than in patients without it among patients with anaphylaxis (65.4% vs 34.6%, \( p = 0.011 \)). With multiple logistic regression analysis after adjustment of age, sex, diabetes, and number of previous contrast exposure, iopromide use was still a risk factor for an anaphylactic shock (OR = 3.088, 95% confidential interval (CI) = 1.078–8.843, \( p = 0.036 \)).

3. Comparison of Clinical Characteristics According to Skin Test Positivity

Fifty-one patients with anaphylaxis followed the recommendation of allergists and underwent RCM skin test and the other 53 patients refused to perform skin test because they did not have a scheduled follow-up CT in the near future.

The mean interval between the time of anaphylaxis and skin test was 14.8 months (IQR 3.4–38.9). Skin test was performed in 41% of patients within one year since they experienced anaphylaxis. The remaining patients underwent skin test at the time when more than one year passed since anaphylaxis occurred (IQR 21.8–64.1).

Among those 51 patients with RCM skin test results, 33 (64.7%) had a positive response to at least one RCM while 18 patients (35.3%) did not show positivity to any RCM tested. In anaphylactic patients accompanied by hypotension, skin test showed 81.8% positivity. Among 33 patients with positive RCM skin test results, mean 1.1 contrast media were positive per person.

Precise information on the culprit RCM was available in 29 patients. Twenty-two (75.9%) patients showed positivity to RCM including their culprit RCM; 14 patients showed single positivity to the culprit RCM; 8 patients showed positivity to other RCMs in addition to the culprit one. Another 7 patients responded to RCM agents other than the culprit one.

The positivity rate of skin test for each contrast agent is varied from 0.0% to 100.0% (Table 2). Iobitridol showed the highest sensitivity (100%) followed by iopromide (59.3%) and iodixanol (50.0%). However, all 5 patients who experienced iohexol induced anaphylaxis were negative in skin test with iohexol.

In patients with a positive RCM skin test, hypotension (79.4% vs. 35.3%, \( p = 0.004 \)) and gastrointestinal symptoms (28.1% vs. 0.0%, \( p = 0.047 \)) were more frequent compared to patients who had a negative RCM skin test. With multiple logistic regression analysis after adjustment by age, sex and diabetes, the presence of hypotension was a characteristic associated with a RCM skin test positivity (OR = 10.0, 95% CI 2.105–47.098, \( p = 0.004 \)). However, skin test positive rate was not different according to the history of previous RCM hypersensitivity reactions, accumulated number of exposures to the RCM, and underlying allergic disease.

Discussion

Incidence of anaphylaxis is increasing rapidly and known to be 4–50/100,000 person-years [16]. In adults, drugs are the most common cause of anaphylaxis [16,17] and radiocounter media was the most commonly involved drug in a study of Korean tertiary care hospital [18]. Although the incidence of RCM hypersensitivity decreased as high-osmolality ionic contrasts were
replaced by low-osmolality non-ionic ones, anaphylactic death still occurred regardless of ionicity [5,6].

Traditionally, immediate hypersensitivity reactions to RCM were considered representative of non-IgE mediated ‘anaphylactoid reaction’ since it can occur on the first exposure and does not always recur on the repeated exposure [1,10,11,19]. However, a previous report showed that only 30% of immediate RCM hypersensitivity developed at the first exposure to RCM [20] and our study also revealed that only 35% of RCM induced anaphylaxis occurred at the first exposures to RCM. We found that milder hypersensitivity symptoms heralded anaphylaxis in 1/3 of the patients on preceding exposure to RCM. Multiple exposures and a previous hypersensitivity reaction prior to RCM induced anaphylaxis suggest that an immunologic mechanism may have some role in the development of some RCM induced anaphylaxis.

Anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction involving at least two or more organs at the same time. However, diagnosis of anaphylaxis can be made if sudden hypotension develops after exposure to a known allergen. Based upon symptoms, anaphylaxis can be classified into mild, moderate, and severe grade [21]. When hypotension occurs as a manifestation of anaphylaxis either as a sole feature or with other symptoms, physicians should pay attention to the development of potential cardiovascular collapse which is the main cause of mortality in anaphylaxis [22]. There are several known risk factors for a severe RCM hypersensitivity such as previous history of RCM hypersensitivity, asthma, allergies requiring medical treatment, use of beta-adrenergic blockers, female gender, Indian and Mediterranean ethnicity, and malignant tumor [23]. However, there was no data on the risk factors for the development of hypotension in anaphylaxis. In this study, we reported risk factors for anaphylactic shock such as older age, previous multiple exposures to RCM, iodopromide use. However, we do not have a clear picture of what the overall anaphylaxis rate is using iodopromide or the other study contrast agents, since patients without anaphylaxis are not included in the study. Secondly, the number of administrations of other contrast agents was too small to provide statistically significant results. In other words, we cannot conclude from this study that iodopromide is more likely to cause anaphylaxis than any of the other contrast agents, but among the anaphylactic patients, iodopromide was associated with more severe forms of anaphylaxis (anaphylaxis with hypotension). In addition, anaphylaxis with hypotension showed stronger association with RCM skin test positivity than anaphylaxis without hypotension. Although skin test positivity might be the result of direct mast cell activation by RCM, it is more likely that IgE mediated hypersensitivity may have a role in the development of RCM induced anaphylaxis when presented with hypotension.

Skin test is widely used to identify the causative agents in IgE mediated hypersensitivity [12,15,16]. Previously, sensitivity of the intradermal test was reported as high as 73% when performed with undiluted solutions [20]. However, this result may have been overestimated by irritation with undiluted RCM and a 1:10 solution has been preferred for intradermal test with RCM in general. The positive rate of the intradermal skin test was variable and reported as low as 4.2% among patients with RCM hypersensitivity [10]. On the other hand, data from the European Network of Drug Allergy multicentre study demonstrated a 50% positive rate of RCM skin test in immediate reactors [14]. Recently, Kim et al. reported that a significantly higher sensitivity positive rate of RCM skin test in severe immediate reactions (57.1%) compared with mild (12.9%) and moderate reactions (25.0%) and suggested their modest utility in evaluating severe adverse reactions retrospectively [24]. In this study, we observed much higher positive rate of RCM skin test in patient with RCM induced anaphylaxis (64.7%). Positive rate went up as high as 81.8% among patients with anaphylactic shock and it is the highest value ever reported in RCM hypersensitivity. Three quarter of patients who showed skin test positivity responded to the very same RCM used at the time of anaphylaxis and cross reactivity rate to other RCMs was low. These findings suggest that a substantial proportion of patients with RCM induced anaphylaxis, especially anaphylactic shock, may have specificity to causative agents and skin tests can provide information on the safe substitutes. However, considering negativity in one third of patients, skin test is not helpful to choose safe alternative RCMs in some populations and clinical reasoning is needed on interpreting the results.

Although we could not perform skin test in negative controls, skin test positivity in the negative control is known to be negligible. There are several studies which elucidated very low positivity of skin test in the negative controls. Brockow et al. reported that positivity of skin test was 0.0% (0/11)–4.2% (3/71) in the negative controls [14]. Kim et al. performed RCM skin testing on 1,048 Korean subjects before contrast-enhanced CT and found only 1 case of positive immediate skin test (0.09%) [24].

There are several limitations in this study. The main limitation is its retrospective design and underreporting of adverse reaction to spontaneous reporting systems. Another limitation is the lack of information on the number of individual RCM used in contrast-

### Table 2. Sensitivity and false negative rate on skin test.

| Causative RCM | Sensitivity | False negative rate |
|---------------|-------------|---------------------|
|               | To any RCM N (%) | To culprit RCM N (%) | To any RCM N (%) | To culprit RCM N (%) |
| Iopromide     | 20/27 (74.1) | 16/27 (59.3) | 7/27 (25.9) | 11/27 (40.7) |
| Iopamidol     | 2/5 (40.0) | 1/5 (20.0) | 3/5 (60.0) | 4/5 (80.0) |
| Iomeprol      | 4/5 (80.0) | 2/5 (40.0) | 1/5 (20.0) | 3/5 (60.0) |
| Iohexol       | 1/5 (20.0) | 0/5 (0.0) | 4/5 (80.0) | 5/5 (100.0) |
| Iobitridol    | 2/2 (100.0) | 1/2 (50.0) | 0/2 (0.0) | 0/2 (0.0) |
| Iodixanol     | 1/2 (50.0) | 0/2 (0.0) | 1/2 (50.0) | 1/2 (50.0) |
| Total         | 30/46 (65.2)* | 22/46 (47.8) | 16/46 (32.6) | 24/46 (52.1) |

*Five patients in whom causal contrast media could not be identified were excluded from this analysis among 51 patients with skin test results.

Iopromide, iopamidol, iomeprol, iohexol, and iobitridol are low-osmolar contrast media. Iodixanol is an iso-osmolar contrast media.
enhanced CT during the study period. Thus, large scale prospective studies including sufficient number of patients reacting to each RCM are needed in order to define the exact incidence and risk factors of RCM induced anaphylaxis.

Conclusion

RCM induced anaphylactic shock is related with multiple exposure to RCM and skin test positivity to RCM.

References

1. Brockow K, Ring J (2011) Anaphylaxis to radiographic contrast media. Curr Opin Allergy Clin Immunol 11: 326–331.
2. Kim MH, Park CH, Kim DI, Kim KM, Kim HK, et al. (2012) Surveillance of contrast-media-induced hypersensitivity reactions using signals from an electronic medical recording system. Ann Allergy Asthma Immunol 108: 167–171.
3. Katayama H (1990) Adverse reactions to contrast media. What are the risk factors? Invest Radiol 25 Suppl 1: S16–17.
4. Thomsen HS, Bush WH Jr (1998) Adverse effects of contrast media: incidence, prevention and management. Drug Saf 19: 313–324.
5. Cashman JD, McCredie J, Henry DA (1991) Intravenous contrast media: use and associated mortality. Med J Aust 155: 618–623.
6. Wysowski DK, Nourjah P (2006) Deaths attributed to X-ray contrast media on U.S. death certificates. AJR Am J Roentgenol 186: 613–615.
7. Williams AN, Kelso JM (2007) Radiocontrast-induced anaphylaxis despite pretreatment and use of iso-osmolar contrast. Ann Allergy Asthma Immunol 99: 467–468.
8. Davenport MS, Cohan RH, Caoli EM, Ellis JH (2009) Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 253: 372–379.
9. Morcos SK, Thomsen HS, Webb JA (2003) Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol 11: 1720–1729.
10. Trcka J, Schmidt C, Seitz CS, Brocker EB, Gross GE, et al. (2008) Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol 190: 666–670.
11. Brockow K, Ring J (2010) Classification and pathophysiology of radiocontrast media hypersensitivity. Chem Immunol Allergy 95: 157–169.
12. Caimmi S, Benyahia B, Suau D, Bousquet-Rouanet L, Caimmi D, et al. (2010) Clinical value of negative skin tests to iodinated contrast media. Clin Exp Allergy 40: 805–810.
13. Sampson HA, Munoz-Furlong A, Campbell RL, Atkinson NF Jr, Bock SA, et al. (2006) Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/ Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117: 391–397.
14. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, et al. (2009) Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 64: 234–241.
15. Goksel O, Aydin O, Atasoy C, Akyar S, Demirel YS, et al. (2011) Hypersensitivity reactions to contrast media: prevalence, risk factors and the role of skin tests in diagnosis-a cross-sectional survey. Int Arch Allergy Immunol 153: 297–305.
16. Lee JK, Vadas P (2011) Anaphylaxis: mechanisms and management. Clin Exp Allergy 41: 923–938.
17. Greenberger PA, Rotskoff BD, Lifschultz B (2007) Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 98: 252–257.
18. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, et al. (2008) Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol 100: 31–36.
19. Maddox TG (2002) Adverse reactions to contrast material: recognition, prevention, and treatment. Am Fam Physician 66: 1229–1234.
20. Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, et al. (2011) Immediate reactions following iodinated contrast media injection: a study of 36 cases. Eur J Radiol 77: 495–501.
21. Muraro A, Roberts G, Clark A, Eigenmann PA, Hallen S, et al. (2007) The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 62: 857–871.
22. Khan BQ, Kemp SF (2011) Pathophysiology of anaphylaxis. Curr Opin Allergy Clin Immunol 11: 319–325.
23. Morcos SK (2005) Review article: Acute serious and fatal reactions to contrast media: our current understanding. Br J Radiol 78: 696–693.
24. Kim SH, Jo EJ, Kim MY, Lee SE, Kim MH, et al. (2013) Clinical value of radiocontrast media skin tests as a prescreening and diagnostic tool in hypersensitivity reactions. Ann Allergy Asthma Immunol 110: 258–262.